Financial considerations of the agreement include development and commercial milestone payments to Opexa of up to $195 M and a tiered royalty rate from the high single digits to the mid-teens based on net sales payable to Opexa. The potential payments to, Financings seem to always set a downward motion to the share pricing – expect a 5-10 depreciation., I have maintained a “BUY” in this market and at this pricing because of the late stage trial status even with a dwindling RegMed universe pricing and visibility. As the BOD … fulfills its responsibility … they will make this appointment permanent in the , If this isn't a SELL – what is , Is there more to come … , VSTM just “trugs” along in the preliminary stages of clinical development with twists and turns but nothing that upsets the apple cart – but great cash position!, $0.01 is dribble. A little early for an “Atta boy.” But, $190 M contingent payments of another $190 M…or $12.97 with terms of: $1.50 in cash up front and 0.2482 of a WMGI share (for total $6.47); 1 contingent value right (CVR) for additional $6.50 cash payable upon FDA approval of BMTI’s Augment Bone Graft an, $4.5 M in restricted common stock and $6 M through the issuance of an 8 amortizing redeemable convertible debenture that matures 6/1, 1/18/13 at $0.62. It is probably an appreciable release but, 10 M shares and warrant Offering at $2.10, A challenge to FDA’s Medical Device Authority … , a lot off issues – trials, A “good to great” clean-up year to … position NBS for the future and specifically that Suzhou Erye is gone replaced by cash, A “Strong BUY” and a price target of $3.00 for end of year FY12. , ACT will pay $12.5 M to the investors, ACTC – the “whirling dervish” of RegMed companies.Can anyone take responsibility to make ACTC a real company – that has good science, Advances in Autologous Whole Blood and Bone Marrow Separation , ALD-401 Safety Data presented at the World Stroke Congress in Brazil, An actionable release – based on increased revenue capacity. CMXI closed at $0.60 and could add $0.05 to $0.10 to their share price with this CE Mark., An overnight deal in a negative surprise – the after-market has been selling off the share to the tune of $2.88 … from the close of $3.32., and their owners are willing to spend “unlimited” amounts of money on their health care, Another significant milestone. The Erye divestiture brings non-dilutive capital that bolsters cash position, anticipated IND filing and clinical data., As usual $0.04 or -3.05 to $1.27. So hold on … still a “Speculative BUY” … but, ASTM, ASTM has “spit the chew” of investor sentiment with investors having NO choice but to allow the new coach to yank the failing seasoned veteran with a rookie reliever . Tough and painful but not surprising with the RegMed, ATHX, ATHX does have a 17 M share offering coming … and the stock has been trading $0.01 to $1.22., Bio-preservation Technology Recognized by 50 Client usage, BioTime (NYSE MKT: BTX) proposes stem cell assets acquisition deal – Issues Open Letter to Shareholders of Geron (GERN), BLFS, BLFS closed on Friday at $0.32 up $0.04 from $0.028 on 1/31/13., Breakdown of Q3/12 Achievements and Highlights and Results -NBS can break the $1.00 trend line by Q1/13. NBS is up $0.03 or 4.61 to $0.669., Breaking down Q3/12 Results and a "BUY" on no legal fanfare on Prochymal worldwide rights, BTX closed at $3.97 on 4/6/13 and is DOWN -$0.01 or -0.25 to $3.96. BTX has been flip-flopping since the 26 of April on small to moderate volumes undermining the 52 week high of $5.07. A HOLD., cancellation of options, Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies approved in Japan …, cash, CEO retires, CMXI closed at $0.47 on 5/9/13. The 50 day moving average is $0.50 compared with the 200 day of $0.63 – the needle needs to be pushed! Investors should compare CMXI to Cytori (CYTX) who is trading at $2.59 as a good hybrid comparable. Let’s watch the stat, collaboration and reverse split , Collaboration as HypoThermosol® Media Demonstrates Improved Storage with Exclusive Distribution Rights for Cellenergy™ Hair Graft Storage Additive, Collaboration with Genzyme/Sanofi Ended , comprised of $2 M in cash, Contract by BARDA to Develop Cell Therapies for Thermal Burns Combined with Radiation Injury – Strong BUY – Stock UP $0.54 or 13.99 to $4.40, CYTX, CYTX closed at $2.52 and is UP $0.04 or 1.599 – expect small volume but a penny or two on a fastly closing Holy week., CYTX closed at $2.93 up $0.08 or $2.63 . A “BUY” with expectation of a $0.10 to $0.20 pop in the next week.CYTX Q4 EPS of -$0.06 beats by $0.10. Revenue of $4.3 M beats by $0.2 M. CYTX made substantial progress in 2012 ., CYTX closed on 11/9 at $3.83 and should be up $0.05-$0.10 in a higher market as shorts has been covering in the recent upward spiral since the earnings release.,

CYTX closed UP at $4.03 on 10/10 and should be UP in a higher opening market; I project a minimum of a $0.10 on this actionable movement, CYTX made significant progress on both the clinical and commercial fronts which will help drive growth in 2013 and beyond.Rated a “BUY” and I anticipate a 10 -20 rise in the share price through the next week! , Dendreon (DNDN) , Detractors beware, down a penny with a larger volume day and … anemic RegMed universe movement.NBS continues a “BUY” as I have been iterating for a while! , drifted DOWN to $0.91 on 5/15/15 on 22.6 K shares. A … HOLD based on revenue “pushes” otherwise KOOL will “drip” downward as 2013 “flo, earnings, Earnings, Earnings-Despite the difficult economic environment and political uncertainty, ethics for a $32 M financing and now the expected tail-spin - The SEC must step in!, existing tissue products provide proof of concept. It could be a huge opportunity with a lot of interest in using cell thera, expect some more huge volumes <like the past 3 days where it had traded on 3/1., Expect … blow back devastating the stock pricing - $0.50 to $0.75 - SELL, FINALLY … a deal structure!!, Financing explains the recent weakness , From a dissenter to an advocate - A “Speculative BUY” ranking ATHX … as the positive tone of the conference call resonated …hopefully, GERN closed on 12/3 at$1.48 up $0.07 or 4.96. This is truly an actionable release … and should affect a sell-off in the stock by the am! GERN is already trading down in the aftermarket -$0.31 or -20.95 to $1.17 and … it isn’t done yet. I pro, getting better with share appreciating, Grifting” the CIRM from Cleveland , growing and even glowing trial results!, HBIO made significant progress. Revenues from continuing operations were $28.2 M for Q4/12 which was within the guidance range of $28-$30 M. BUY!, I am – skeptical - A “SELL” but, I believe a “BUY” for this “cheap” stock, I believe – it was a long shot anyway! Status quo is maintained as CYTX is still pursuing the primary path to market – a PMA filing to capture the market opportunity they wanted., I consider CYTX a … BUY … and value reducing costs and decreasing the net losses while structuring their guidance to highlight their current service agreements with BARDA and other sources. Regaining full , I continue to reiterate this as a “BUY” on downdraft … still sticking to BLFS being under-valued –with a target of $0.50 by years end since the stock has already visited $0.45 on 11/23/12. I could foresee a $0.05 to $0.10 rise based on the thinly , I very optimistic about BLFS, in this market who knows – my view still worth $0.01 to $0.03 in view of the lack of sector news. AMR-001 now enjoys greater protection in terms of its CD34 cell conte, including dendritic cells, Investigator-Sponsored Cell Therapy Clinical Study for Scleroderma Initiated in France , ipo-analysis, It couldn’t have come at a time when so many issues are in play – i.e. their pending $25 million fund raising initiative(s). , it is an actionable release but, it seems a … meaningless one to me and, it will depend on trial design but, KOOL closed UP $0.03 to $0.91 on 5/13/12 on 65.5 K shares; was UP again $0.05 to $0.95 on 5/14 with 32.4 K shares but, leapfrog the “valley of death”-Another view of STEM reaping stem cell funds despite CIRM's panel’s advice, long-ideas, Loses long-shot legal challenge but, Many will “balk” at the pricing and the dilution – but only the public markets could offer a redemption if milestones are defined and met., market-outlook, Mesoblast’s (ASX: MSB) (USOTC: MBLTY) P2 clinical trial for lumbar spinal fusion had successfully met its safety and efficacy endpoints. Results support progression of clinicals to P3., Money launches commercialization, NBA opened UP $0.03 or 5.56 to $0.62., NBS, NBS closed at $0.61, NBS closed at $0.63 and this event should add $0.01 to $0.03 to the share price., NBS closed at $0.69 with solid volume of 1.127 M shares as futures hold gains with a trading expectation $0.01 to $0.02 to drive the shares above $0.70. NBS is one company that has … GOOD news in the last few days., NBS closed on last Friday, NBS is UP $0.02 or 3.46 to $0.58.,

NBS’ PCT expertise in GMP manufacture for cell therapies, New Publication That Supports Positive Results, New published data is consistent with Amorcyte’s trial results , Nobody wants to kick a dead horse but get the fork lift to move the R D legacy out of the stable!, Non-dilutionary funding is definitely a … truly actionable event… CMXI closed down yesterday at $0.69. I would anticipate a $0.15 to $0.20 upward movement if not more as we are in a depreciating market. MY hypothesis is a “STRONG BUY” as I already had a “, Not BAD considering the total refocus and spin-out of the China driven business to stabilize the on-going business and AMR-001 development cycle … a BUY. An offering is done – $10.7 million so it is time to show what NBS can do to focus , not great but, now that Q4 and FY12 results are out – my expectations are on target – yet again as BLFS focuses another “rebound” play! The 50 day moving average is up to $0.30 and the 200 day average is up $0.28. The float is only 1, omission, on my just … wait and see list. , One might say, OSIR, Patent Infringement Complaint also requests INJUNCTION on US sales , Patterns of hype, Pluristem – check your rear-view mirror – why did so many “opine” and react to the Bloomberg article , plus legal expenses, Prices $15 M of Senior Secured Convertible Notes Warrants , Prochymal® (remestemcel-L) will be evaluated under its Rapid Authorization Procedures, Product Candidate Targets Orthopedic and Sports Injuries...A very plausible application but, PSTI, PSTI closed at $2.97 and is UP $0.09 or 3.03 to $3.06 in the pre-market. I would add another $0.05-$0.07 to the current movement by the close of day. A “BUY”., Q3 Highlights and Achievements, Q3/12 Results, Q3/12 Results with a BUY ranking, quick-picks-lists, raises the barrier of entry for any competitor, Ranked a "BUY", Receives Notification of $1.2 M NIH Grant Award for 1st Clinical Study of VSEL(TM) Technology in Humans, Redeems all outstanding shares of its Series E 7 Senior Convertible Preferred Stock, reduces legal and financial reporting expenditures, RegMed Sector, return of shares and warrants. , SELL on earnings release but come back when it settles down, Sell on the strength and news, short-ideas, simplifies financial statements and focuses efforts exclusively on the rapidly growing, stem cells and T cells is being … more recognized., STEM closed at $1.90 on 4/9 up a penny from for 4/8/13. A ... BUY on the CIRM funding, STML closed at $10.98 following Wednesday’s $10.98 with 167.5 K share traded post the IPO of 1.1525 M shares trading at $11.80, STML closed at $14.96 0n 5/3/13 and has 3.44 M shares outstanding and a float of 2.09 M. So, Structure And Pricing Begins, structure and pricing begins, Subsidiary Financing-“control” … only goes so far … how does BTX “optimize” the total value versus the inherent value of the individual units, The 50 day moving average is lower at $0.60 as the 200 day average had fallen to $0.75. Visibility is still an issue but the financing got done! 35.78 M shares are held by insiders with a weak institutional following of .1 . Ra, the debate will continue whether any cell therapy can alter the natural history of severe ischemic induced cardiovascular disease and in doing so provide a meaningful clinical benefit., The equine market is often under-appreciated as an important part of the animal health market. There are approximately 10.5 M horses in the US, The grant news is actionable … as any monies in effect valuation … $0.02 to $0.05 – on this one., The newest milestone; 9 straight quarter of record revenue with 135 year-over-year growth in Q3/12 revenues as well as 2012 Full Year revenue guidance being increased to $5 M – could investors ask for more from BLFS. , The Pending War Of Letters, The primary safety and tolerability endpoints of the P1 program were met. Let’s see how the P2 study progresses for the treatment of pain.VSTA closed at $0.79 on 1/22/13 with increasing volume of 13.5 K shares from the past days of 0. Look for VSTA to ope,

The underlying shares were previously registered but the registration statement expired under relatively recent SEC rules - needed to be refreshed. , There better be … a rabbit or two in ATHX’s hat!, These patents deliver major commercial advantages and offer long term protection in these territories for the company’s products based on its proprietary Mesenchymal Precursor Cell (MPC) adult stem cell technology platform. MSBLTY closed at $34.54 on 2/6/, They needed the cash! Look and understand the list of companies who have financed in the past months – like Athersys (ATHX) and Cytori (CYTX). At least … CMXI has REVENUE, TNGN closed at $1.35 down with 16.7 K volume on 1/31/13 and has been slipping up and down since 1/2/13. I project at least a 1-3 pop in the stock !, To be expected … what is interesting is … The warrants are exercisable immediately upon issuance and have a 4 year term and an exercise price of $3.00 per share. The offering is expected to close on or about 2/11/13., Traders love them today but, Tthe pending war of letters, Under the terms of the settlement, validating the ”spoken word” re partnering potential. , What did I hear new – nothing – radio silence – same message working on all fronts in multiple and proposed efforts! ATHX closed at $2.12 after running the gamut in the May period and mid-April. ATHX was DOWN -5.7 on 27 K shares in yesterday’s after-mark, Who will be the NEXT … to STRENGTHEN … their company perception and stock pricing!! , why … not at this price which will suffer a little by dilution. STML is already DOWN -$0.62 or -4.14 to $14.34 – look for it to even out at $14.00., will sell them tomorrow, “BUY” – NBS had closed down at $0.53. Expectation is that NBS will regain its $0.60-$0.61 position – so